377 Menopause and Its Relationship With Immunostaining and Tumor Growth Patterns in Nonfunctioning Pituitary Adenomas: A Clinicopathologic Study

View at publisher Summarise with VIRAT
Authors: Erica Gillespie, Amara Emeh, Miranda Perez, David J. Coté, Sindhu Daggupati, Apurva Prasad, William Zeng, David Gomez, Ishan Shah, Jonathan Sisti, Robert G. Briggs, Kyle M. Hurth
+2 more John David Carmichael, Gabriel Zada
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: As the pituitary gland plays an integral role in age-related hormonal changes, menopause status may influence nonfunctioning pituitary adenoma (NFPA) characteristics. The effects of menopause on pituitary adenoma characteristics have not been studied in detail. METHODS: We conducted a retrospective review of a prospectively maintained REDCap database from the University of Southern California Pituitary Center. Patients were included in the study if they were female patients diagnosed with an NFPA requiring surgical resection between 2012 and 2023. Patients were assigned to groups based on their menopausal status and presence of hypogonadotropic hypogonadism (HGHG). Univariable statistics were used to measure associations between menopausal status and HGHG status and immunohistochemistry and tumor invasion patterns. RESULTS: 96 (44.2%) pre-menopausal patients (average age 40.6 ± 7.1) and 121 (55.8%) post-menopausal patients (average age 59.7 ± 9.2) were included in the analysis. 185 (85.3%) patients had available IHC staining. NFPAs in post-menopausal women were more likely to stain for SF-1 (OR = 6.04, 95% CI: 1.90-19.19, p-value = 0.0030), and were less likely to stain for TPIT (OR= 0.22, 95% CI: 0.08-0.67, p-value = 0.0105) or TSH (OR = 0.08, 95% CI: 0.01-0.69, p-value = .0115). NFPAs in post-menopausal women were also more likely to exhibit infrasellar invasion (OR = 6.32, 95% CI: 1.73-23.09, p-value = 0.0051), except for post-menopausal women diagnosed with HGHG (OR = 0.30, 95% CI: 0.12-0.75, p-value = .0149). Pre-menopausal women on oral contraceptive pills (OCP) had tumors that were more likely to stain positive for ACTH (OR = 4.50, 95% CI: 1.42-14.25, p-value = 0.0179). Estrogen use in post-menopausal women was not associated with IHC subtype. Maximum tumor diameter was significantly larger in the pre-menopausal HGHG cohort (p-value = 0.05). CONCLUSIONS: Menopausal status is associated with differences in immunostaining subtype and NFPA growth patterns, with postmenopausal women being more likely to harbor tumors positive for SF-1 with infrasellar invasion, and less likely TPIT and TSH. The role of hormonal changes related to menopause and NFPA pathogenesis warrants further study.

Fields of Study & Subjects

Pituitary Gland Disorders and Treatments Neuroendocrine Tumor Research Advances Meningioma and schwannoma management

Publication details

Journal / source
Neurosurgery
Volume
72
Issue
Supplement_1
Pages
103–103
Publication date
26 March 2026
Language
EN